SCHEMBL13132007

SCHEMBL13132007

COCCCOc1cc(CBr)cc2cccc(F)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.39
TDP1 Q9NUW8 3/20 0.39
SMN1; SMN2 Q16637 4/20 0.34
NPC1 O15118 4/20 0.34
RAB9A P51151 3/20 0.34
LMNA P02545 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 4/20 0.33
HPGD P15428 3/20 0.33
MAPK1 P28482 2/20 0.33
ALDH1A1 P00352 2/20 0.33
PDE4D Q08499 1/20 0.33
KDM4E B2RXH2 1/20 0.33
KCNH2 Q12809 1/20 0.32
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13131332 0.88 L3MBTL1 (0.37) L3MBTL1TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL13131957 0.87 L3MBTL1 (0.36) L3MBTL1TDP1KMT2AALDH1A1PDE4D
SCHEMBL13132072 0.80 KMT2A (0.42) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL2808494 0.78 REN (0.45) L3MBTL1TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL3977294 0.76 L3MBTL1 (0.39) L3MBTL1TDP1KMT2AALDH1A1KDM4E
SCHEMBL13132008 0.75 L3MBTL1 (0.34) L3MBTL1TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL13131927 0.73 PTPN11 (0.44) L3MBTL1TDP1LMNAHPGDALDH1A1
SCHEMBL1039963 0.71 REN (0.48) L3MBTL1TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL13132005 0.70 REN (0.34) L3MBTL1TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL13131977 0.70 REN (0.48) L3MBTL1TDP1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 L3MBTL1 4737/4885TDP1 4607/4885SMN1; SMN2 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.